메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials

SYDNEY, Dec. 16, 2025 -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening. Commissioned by the Thoracic Research Centre at the University of Queensland and developed in partnership with Queensland Health, Screen2Quit is a revised, clinical version of the My QuitBuddy application redeveloped and instrumented to collect participant backend data for a multi-year randomised contr
- 김갑성 기자
- 2025-12-16 05:07
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)

CHENGDU, China, Dec. 15, 2025 -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next two years, aligned with the SBTi's stringent criteria. This commitment entails the future development and implementation of a series of emission reduction measures designed to cut the company's greenhouse gas emissions across its value chain to a level consistent with the 1.5°C temperature goal
- 김갑성 기자
- 2025-12-15 22:30
PM-International expands child sponsorships to 8,000 with €2.88 million donation

SCHENGEN, Luxembourg, Dec. 15, 2025 -- Global support for children in need is declining rapidly. According to World Vision, governments and institutions worldwide have cut funding for children's aid by $16.3 billion, limiting access to food, healthcare and education for millions of vulnerable children. At the same time, PM-International is expanding its commitment through its charity Foundation PM We Care. In 2026, it will increase the commitment to the partnership with World Vision by supporting an additional 1,400 children, raising the total number of sponsored children to 8,0
- 김갑성 기자
- 2025-12-15 22:13
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE

NEW YORK, Dec. 15, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th Stocks are fractionally higher early Monday as a busy week of economic data begins, with non-farm payrolls and retail sales Tuesday, and November CPI Thursday. Seven of the ten largest IPOs of 2025 debuted on the NYSE, including Circle, Figma, and Klarna. NYSE President Lynn Martin said the 2026
- 황정호 기자
- 2025-12-15 22:10
Neurabody Enters the UK Market with Selfridges Launch, Showcasing the Future of AI-Driven Ergonomics

LONDON, Dec. 15, 2025 -- Neurabody, the AI-driven posture science company transforming modern ergonomics, today announced its official launch at Selfridges London, marking a significant milestone in the company's global expansion and consumer entry into the UK market. With this debut, Selfridges customers will experience NeuraSit, Neurabody's intelligent posture-support system that merges ergonomic engineering, embedded sensors, and real-time AI feedback to help users improve posture effortlessly. The product will be featured within Selfridges' curated mix of forward-thinking t
- 김갑성 기자
- 2025-12-15 22:00
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs. Da
- 김갑성 기자
- 2025-12-15 22:00
피엠인터내셔널, 후원 아동 8천 명으로 확대…288만 유로 기부로 사회 공헌 리더십 강화

솅겐, 룩셈부르크, 2025년 12월 15일 -- 피엠인터내셔널(이하 PMI, Founder & CEO 롤프 소르그 회장)이 자선 재단인 'PM 위 케어(PM We Care)'를 통해 자선 나눔 활동 확대에 나섰다. PMI는 2026년까지 국제구호개발 월드비전과의 파트너십을 강화하고, 1,400명의 아동을 추가로 후원하여 총 후원 아동 수를 8,000명으로 늘리고 연간 기부금 역시 288만 288만 유로(약 39억 원)로 증액해 프로그램을 더욱 공고히 할 계획이다. 월드비전에 따르면, 전 세계 정부와 기관들이 아동 지원 기금을 163억 달러(한화 약 22조 원) 삭감하면서 수백만 명의 취약계층 아동들이 식량을 비롯한 의료 서비스 등의 접근에 제한을 받고 있는 것으로 나타났다. PMI 비키 소르그 자선 대사는 "모든 '피트라인' 제품 구매는 전 세계의 팀파트너들이 후원 아동에게 '한 시간의 삶'을 선물하는 것"이라며 "우리는 계속해서 월드비전의 든든한 파트너가 되고자 한다"고 전했다. Picture is available at AP 담당자 정보
- 김갑성 기자
- 2025-12-15 22:00
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona's INHBE program. Scientific and industry interest in INHBE has accelerated, supported by compelling human genetic evidence and emerg
- 김갑성 기자
- 2025-12-15 21:00
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

TAIPEI, Dec. 15, 2025 -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research and industrial applications. The integration provides Leadgene Biosolutions with a clear direction and expanded opportunities in
- 김갑성 기자
- 2025-12-15 21:00
Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia

SINGAPORE, Dec. 15, 2025 -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials. The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system. Curie Oncology: using AI to bring more trials to patients Curie Oncology currently r
- 김갑성 기자
- 2025-12-15 19:26

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분